Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 164

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

HER‐2 pulsed dendritic cell vaccine can eliminate HER‐2 expression and impact ductal carcinoma in situ

Open access
Sharma, Anupama, Koldovsky, Ursula, Xu, Shuwen, Mick, Rosemarie, Roses, Robert, Fitzpatrick, Elizabeth, Weinstein, Susan, Nisenbaum, Harvey, Levine, Bruce L., Fox, Kevin, Zhang, Paul, Koski, Gary, Czerniecki, Brian J. · 2012 · Cancer

Abstract

BACKGROUND: HER‐2/neu overexpression plays a critical role in breast cancer development, and its expression in ductal carcinoma in situ (DCIS) is associated with development of invasive breast cancer. A vaccine targeting HER‐2/neu expression in DCIS may initiate immunity against invasive cancer. METHODS: A HER‐2/neu dendritic cell vaccine was administered to 27 patients with HER‐2/neu–overexpressing DCIS. The HER‐2/neu vaccine was administered before surgical resection, and pre‐ and postvaccination analysis was conducted to assess clinical results. RESULTS: At surgery, 5 of 27 (18.5%) vaccinated subjects had no evidence of remaining disease, whereas among 22 subjects with residual DCIS, HER‐2/neu expression was eradicated in 11 (50%). When comparing estrogen receptor (ER)neg with ER pos DCIS lesions, vaccination was more effective in hormone‐independent DCIS. After vaccination, no residual DCIS was found in 40% of ER neg subjects compared with 5.9% in ER pos subjects. Sustained HER‐2/neu expression was found in 10% of ER neg subjects compared with 47.1% in ER pos subjects (P = .04). Postvaccination phenotypes were significantly different between ER pos and ER neg subjects (P = .01), with 7 of 16 (43.8%) initially presenting with ER pos HER‐2/neupos luminal B phenotype finishing with the ER pos HER‐2/neuneg luminal A phenotype, and 3 of 6 (50%) with the ER neg HER‐2/neupos phenotype changing to the ER neg HER‐2/neuneg phenotype. CONCLUSIONS: Results suggest that vaccination against HER‐2/neu is safe and well tolerated and induces decline and/or eradication of HER‐2/neu expression. These findings warrant further exploration of HER‐2/neu vaccination in estrogen‐independent breast cancer and highlight the need to target additional tumor‐associated antigens and pathways. Cancer 2012. © 2012 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.26734

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 164

Metadata

Authors
Sharma, A., Koldovsky, U., Xu, S., Mick, R., Roses, R., Fitzpatrick, E., Weinstein, S., Nisenbaum, H., Levine, B. L., Fox, K., Zhang, P., Koski, G., & Czerniecki, B. J.
Venue
Cancer
Publisher
Wiley
Published
2012-01-17
Volume
118
Issue
17
Pages
4354-4362
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1564805122
Cited by
164
References
2
FWCI
5.67
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HER‐2 pulsed dendritic cell vaccine can eliminate HER‐2 expression and impact ductal carcinoma in situ. https://app.cochat.ai/papers/10.1002/cncr.26734
The paper
Sharma, A., Koldovsky, U., Xu, S., Mick, R., Roses, R., Fitzpatrick, E., Weinstein, S., Nisenbaum, H., Levine, B. L., Fox, K., Zhang, P., Koski, G., & Czerniecki, B. J. (2012). HER‐2 pulsed dendritic cell vaccine can eliminate HER‐2 expression and impact ductal carcinoma in situ. Cancer. https://doi.org/10.1002/cncr.26734

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.